Although it does not represent a suitable oncoantigen, since its expression does not strictly affect tumor behavior; however, since it is a tumor associated antigen it could represent an interesting target for the development of antibody-mediated therapy on the subset of NSCLC which are p53 null and ADORA3 positive. Here, ADORA3 is linked to non-small cell lung carcinoma.